PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.23 +0.76%

+$0.60 today

Market cap
$5.03B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 0.64M

Average 1.27M

PTCT Account Payables

Amounts the company owes suppliers for goods and services received.

PTC Therapeutics, Inc.NASDAQ: PTCT

Account Payables · Q2 FY2026 · quarter ended Jun 2026

Account payables rises 52.6% from a year ago

Account payables stood at $40.45M at the end of Q2 FY2026, up 52.6% from a year earlier and up 58.7% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.

Context

  • Account payables amounted to 1.2% of total assets at the end of Q2 FY2026, up 0.2 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +52.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$40.45M+58.7% QoQ
Last fiscal yearDec 2025
$45.49M+163.3% YoY
Year agoJun 2025
$26.51M+52.6% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.6%——
1 year+163.3%——
3-year CAGR+18.6%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
45.49M USD
Year-over-year change
+163.3%
4-year CAGR
+18.5%

Account Payables vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's Jun 2026 account payables of $40.45M is the 3rd highest of the 11 companies compared; the peer median is $15.61M.
  • Its year-over-year change of +52.6% is the 2nd highest of 11, against a peer median of -12.4%.
  • Account payables amounts to 1.2% of total assets for PTCT, versus a peer median of 1.3%.
PTCT Competitors Peer median
Account Payables for PTCT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SRPTSarepta Therapeutics, Inc.Mar 2026$70.38M -54.9%+43.1%2.2%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$42M -11.5%-10.5%3.2%
PTCTPTC Therapeutics, Inc.Jun 2026$40.45M +52.6%+18.6%1.2%
BBIOBridgeBio Pharma, Inc.Jun 2026$27.2M +4.1%+46.3%2.2%
IONSIonis Pharmaceuticals, Inc.Sep 2026$27.11M +89.3%+16.2%0.9%
WVEWave Life Sciences Ltd.Mar 2026$19.06M +32.8%-2.5%3.3%
DYNDyne Therapeutics, Inc.Jun 2026$12.15M -13.3%+15.4%1.2%
KRYSKrystal Biotech, Inc.Jun 2026$6.54M -8.1%-6.7%0.4%
SLDBSolid Biosciences Inc.Mar 2026$5.56M -13.6%-0.1%1.3%
CAPRCapricor Therapeutics, Inc.Mar 2026$3.93M -25.2%-30.0%1.2%
BMRNBioMarin Pharmaceutical Inc.Sep 2026$0 -100.0%+10.6%0.0%
Peer median (excluding PTCT) $15.61M-12.4%+5.2%1.3%

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents189.72M279.83M594M779.71M984.65M
Short-term Investments583.66M130.87M282.74M359.99M960.72M
Net Receivables110.46M155.61M160.82M158.55M181.62M
Inventory15.86M21.81M30.58M23.19M79.65M
Other Current Assets0105.66M150.49M44.09M67.31M
Total Current Assets954.37M693.79M1.22B1.37B2.27B
Property, Plant & Equipment (Net)130.01M175.02M178.99M117.66M135.42M
Goodwill82.34M82.34M82.34M82.34M82.34M
Intangible Assets724.84M705.89M379.5M118.79M388.75M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets46.5M48.58M36.25M20.7M18.3M
Total Non-current Assets983.69M1.01B677.07M339.49M624.82M
Total Assets1.94B1.71B1.9B1.71B2.9B
Account Payables23.03M27.27M6.05M17.27M45.49M
Short-term Debt208.83M72.15M194.31M257.82M569.63M
Tax Payables1.29M4.71M04.7M0
Deferred Revenue01.35M801K5.51M2.04M
Other Current Liabilities118.86M126.46M139.82M120.22M202.93M
Total Current Liabilities509.35M406.24M603.1M580.98M968.43M
Long-term Debt956.59M1.26B1.9B2.11B2.03B
Deferred Tax Liabilities137.11M102.83M55.91M00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities239.9M166.64M36.44M22.23M13.7M
Total Non-current Liabilities1.43B1.65B2.11B2.22B2.14B
Total Liabilities1.94B2.05B2.71B2.8B3.1B
Common Stock71K72K75K77K80K
Retained Earnings(2.1B)(2.66B)(3.28B)(3.65B)(2.96B)
Accumulated OCI(24.28M)4.8M(1.29M)(25.89M)10.5M
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.44M(347.09M)(818.56M)(1.1B)(205.31M)
Total Debt1.27B1.46B2.23B2.47B2.71B
Net Debt1.08B1.18B1.64B1.69B1.72B

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.